Literature DB >> 3917973

Mutation at I-A beta chain prevents experimental autoimmune myasthenia gravis.

P Christadoss, J M Lindstrom, R W Melvold, N Talal.   

Abstract

Immune response (Ir) gene(s) at the I-A subregion of the mouse H-2 complex influence susceptibility to experimental autoimmune myasthenia gravis (EAMG). To determine the importance of the Ir gene product, the Ia antigens, in EAMG pathogenesis, we studied the degree of EAMG susceptibility of an I-A mutant strain, the B6.C-H-2bm12 (bm12), and its parent B6/Kh. According to the cellular, humoral, biochemical, and clinical manifestations of EAMG, the I-A mutation converted an EAMG susceptible strain (B6/Kh) into a relatively resistant strain (bm12). The relative resistance to EAMG induction in bm12 may be due to the lack of Ia.8 and/or Ia.39 determinants and/or quantitative expression of Ia antigens.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3917973     DOI: 10.1007/bf00372239

Source DB:  PubMed          Journal:  Immunogenetics        ISSN: 0093-7711            Impact factor:   2.846


  24 in total

1.  B6.C-H-2bm12. A new H-2 mutation in the I region in the mouse.

Authors:  I F McKenzie; G M Morgan; M S Sandrin; M M Michaelides; R W Melvold; H I Kohn
Journal:  J Exp Med       Date:  1979-12-01       Impact factor: 14.307

2.  HLA antigens and myasthenia gravis in Japan.

Authors:  T Yoshida; M Tsuchiya; A Ono; H Yoshimatsu; E Satoyoshi; K Tsuji
Journal:  J Neurol Sci       Date:  1977-06       Impact factor: 3.181

3.  Neuromuscular junction in myasthenia gravis: decreased acetylcholine receptors.

Authors:  D M Fambrough; D B Drachman; S Satyamurti
Journal:  Science       Date:  1973-10-19       Impact factor: 47.728

Review 4.  Autoimmune response to acetylcholine receptors in myasthenia gravis and its animal model.

Authors:  J Lindstrom
Journal:  Adv Immunol       Date:  1979       Impact factor: 3.543

5.  Genetic control of experimental autoimmune myasthenia gravis in mice. I. Lymphocyte proliferative response to acetylcholine receptors is under H-2-linked Ir gene control.

Authors:  P Christadoss; V A Lennon; C David
Journal:  J Immunol       Date:  1979-12       Impact factor: 5.422

6.  Reconstitution of Ir genes, Ia antigens, and mixed lymphocyte reaction determinants by gene complementation.

Authors:  C G Fathman; M Kimoto; R Melvold; C S David
Journal:  Proc Natl Acad Sci U S A       Date:  1981-03       Impact factor: 11.205

7.  HLA-A, -B, -C and -D antigens in male patients with myasthenia gravis.

Authors:  J Säfwenberg; L Hammarström; J B Lindblom; G Matell; E Möller; P O Osterman; C I Smith
Journal:  Tissue Antigens       Date:  1978-08

8.  Genetic control of the immune response to haemoglobin. III. Variant A beta (bm12) but not Ae (D2.GD) Ia polypeptides alter immune responsiveness towards the alpha -subunit of human haemoglobin.

Authors:  C J Krco; A L Kazim; M Z Atassi; R Melvold; C S David
Journal:  J Immunogenet       Date:  1981-12

9.  Genetic control of autoimmunity to acetylcholine receptors: role of Ia molecules.

Authors:  P Christadoss; V A Lennon; C J Krco; E H Lambert; C S David
Journal:  Ann N Y Acad Sci       Date:  1981       Impact factor: 5.691

10.  Linkage between the frequency of muscular weakness and loci that regulate immune responsiveness in murine experimental myasthenia gravis.

Authors:  P W Berman; J Patrick
Journal:  J Exp Med       Date:  1980-09-01       Impact factor: 14.307

View more
  15 in total

1.  Experimental autoimmune myasthenia gravis in the mouse.

Authors:  B Wu; E Goluszko; P Christadoss
Journal:  Curr Protoc Immunol       Date:  2001-05

2.  Ek alpha transgene in B10 mice suppresses the development of myasthenia gravis.

Authors:  P Christadoss; C S David; M Shenoy; S Keve
Journal:  Immunogenetics       Date:  1990       Impact factor: 2.846

Review 3.  Myasthenia gravis: an autoimmune response against the acetylcholine receptor.

Authors:  Y M Graus; M H De Baets
Journal:  Immunol Res       Date:  1993       Impact factor: 2.829

4.  Oral administration of a dual analog of two myasthenogenic T cell epitopes down-regulates experimental autoimmune myasthenia gravis in mice.

Authors:  M Paas-Rozner; M Dayan; Y Paas; J P Changeux; I Wirguin; M Sela; E Mozes
Journal:  Proc Natl Acad Sci U S A       Date:  2000-02-29       Impact factor: 11.205

Review 5.  Structural variation among major histocompatibility complex class-II genes which predispose to autoimmunity.

Authors:  G T Nepom
Journal:  Immunol Res       Date:  1989       Impact factor: 2.829

6.  Oral administration of an immunodominant T-cell epitope downregulates Th1/Th2 cytokines and prevents experimental myasthenia gravis.

Authors:  F Baggi; F Andreetta; E Caspani; M Milani; R Longhi; R Mantegazza; F Cornelio; C Antozzi
Journal:  J Clin Invest       Date:  1999-11       Impact factor: 14.808

7.  Autoimmune T lymphocytes in myasthenia gravis. Determination of target epitopes using T lines and recombinant products of the mouse nicotinic acetylcholine receptor gene.

Authors:  A Melms; S Chrestel; B C Schalke; H Wekerle; A Mauron; M Ballivet; T Barkas
Journal:  J Clin Invest       Date:  1989-03       Impact factor: 14.808

8.  In vitro proliferative responses and antibody titers specific to human acetylcholine receptor synthetic peptides in patients with myasthenia gravis and relation to HLA class II genes.

Authors:  S Brocke; C Brautbar; L Steinman; O Abramsky; J Rothbard; D Neumann; S Fuchs; E Mozes
Journal:  J Clin Invest       Date:  1988-12       Impact factor: 14.808

Review 9.  The molecular basis of susceptibility to rheumatoid arthritis: the conformational equivalence hypothesis.

Authors:  R J Winchester; P K Gregersen
Journal:  Springer Semin Immunopathol       Date:  1988

10.  Mapping myasthenia gravis-associated T cell epitopes on human acetylcholine receptors in HLA transgenic mice.

Authors:  Huan Yang; Elzbieta Goluszko; Chella David; David K Okita; Bianca Conti-Fine; Teh-sheng Chan; Mathilde A Poussin; Premkumar Christadoss
Journal:  J Clin Invest       Date:  2002-04       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.